Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirofiban plus aspirin in moderate to severe perforator atherosclerotic cerebral infarction (BAD)
ChiCTR2200055421Phase 4Recruiting
- Sponsor
- Chengdu Second People's Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tirofiban in ischemic stroke and branch atheromatous disease (BAD) (2 arms), sponsored by Chengdu Second People's Hospital. Primary endpoints: Progression of stroke severity and Good 90-day functional prognosis. Started Mar 2022; status: recruiting.
02
Drugs
tirofiban
03
Conditions
ischemic strokebranch atheromatous disease (BAD)
Beyond the preview
Go deeper on ChiCTR2200055421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055421.